Unknown

Dataset Information

0

First-in-man allopregnanolone use in super-refractory status epilepticus.

ABSTRACT: Super-refractory status epilepticus (SRSE) is associated with high morbidity and mortality. Treatment of SRSE is complicated by progressive cortical hyperexcitability believed to result in part from synaptic GABA receptor internalization and desensitization. Allopregnanolone, a neurosteroid that positively modulates synaptic and extrasynaptic GABAA receptors, has been proposed as a novel treatment. We describe the first two patients with SRSE who were each successfully treated with a 120-h continuous infusion of allopregnanolone. Both patients recovered from prolonged SRSE with good cognitive outcomes.

SUBMITTER: Vaitkevicius H 

PROVIDER: S-EPMC5454395 | biostudies-other | 2017 Jun

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

First-in-man allopregnanolone use in super-refractory status epilepticus.

Vaitkevicius Henrikas H   Husain Aatif M AM   Rosenthal Eric S ES   Rosand Jonathan J   Bobb Wendell W   Reddy Kiran K   Rogawski Michael A MA   Cole Andrew J AJ  

Annals of clinical and translational neurology 20170426 6

Super-refractory status epilepticus (SRSE) is associated with high morbidity and mortality. Treatment of SRSE is complicated by progressive cortical hyperexcitability believed to result in part from synaptic GABA receptor internalization and desensitization. Allopregnanolone, a neurosteroid that positively modulates synaptic and extrasynaptic GABA<sub>A</sub> receptors, has been proposed as a novel treatment. We describe the first two patients with SRSE who were each successfully treated with a  ...[more]